Titan Pharmaceuticals Inc 's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Titan Pharmaceuticals Inc 's ROA in the second quarter of 2025?
Titan Pharmaceuticals Inc recorded a cumulative net loss of $-3 million during 12 months ending in the second quarter of 2025, resulting in a negative return on assets (ROA) of -95.64%.

However, within the Healthcare sector 774 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2025 quarter, so far to 4438, from total ROA ranking in the first quarter of 2025 at 4627.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Total Assets Change	-29.86 %	-67.4 %	-63.57 %	-63.63 %	435.71 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-3	-4	-5	-6	-5
Return On Assets (TTM)	-95.64 %	-129.2 %	-107.63 %	-104.23 %	-75.61 %
TTNP's Total Ranking	# 4438	# 4627	# 5256	# 4624	# 4523
Total Assets (TTM) in million	3	2	3	4	4
Seq. Total Assets Change	41.51 %	-26.24 %	-18.85 %	-17.2 %	-34.23 %
Seq. Net Income Change	-	-	-	-	-

TTNP's 5 Years Annual ROA >> Back to TTNP Management Effectiveness >> Compare TTNP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 123
Sector	# 775
Overall	# 4379

Return On Assets Statistics
High	Average	Low
120.16 %	-76.62 %	-254.32 %
(Dec 31 2013)		(Jun 30 2023)

Financial Statements
Titan Pharmaceuticals Inc 's Assets	$ 3 million	TTNP's Balance sheet
Titan Pharmaceuticals Inc 's Income	$ -1 million	Quarterly TTNP's Income Statement
TTNP's Income by Division		See TTNP's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	-63.57 %	97.71 %	-49.24 %	0.6 %	-12.92 %
Total Assets in million	3	8	4	8	8
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-5	-6	-10	-9	-18
Annual Return On Assets	-161 %	-69.41 %	-251.5 %	-109.78 %	-229.57 %

TTNP's 5 Years Annual ROA >> Back to TTNP Management Effectiveness >> Compare TTNP ROA to its Competitors

More Return On Assets Ratios
TTNP's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
TTNP's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for TTNP's Competitors
Subscribers only: Roa for Titan Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for TTNP's Customers

You may also want to know
TTNP's Roi	TTNP's Inventory Turnover Ratio	TTNP's Growth Rates	TTNP's Dividend Comparisons
	TTNP's Profitability Ratios	TTNP's Asset Turnover Ratio	TTNP's Dividend Growth
TTNP's Roe	TTNP's Valuation Ratios	TTNP's Financial Strength Ratios	TTNP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector

ROA

Date modified: 2026-08-29T17:31:39+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.